SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Twos quarterly report and unchanged bookings outlook are prompting debate, while managements report that GTA VI preorders are far above expectations keeps attention on the approaching launch. Many traders are bullish on the games sales and future online spending, while others point to the softer quarter and unchanged outlook as reasons for caution and a possible sell-the-news reaction.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desks quarterly earnings beat and stronger-than-expected next-quarter guidance sparked a sharp rally, but traders focused on the subsequent fade during managements call. The community is split between seeing the results and expanded buyback authorization as signs of a turnaround and worrying that flat-to-lower sales, margin pressure, and cautious commentary point to continued growth challenges.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 470,841,831.5537221 with 445,839,831.5537221 in circulation. The last known price of Avalanche is 8.67923054 USD and is up 8.47 over the last 24 hours. It is currently trading on 1134 active market(s) with $528,273,140.94 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

Traders are reacting to reports that the NYSE selected Avalanche for clearing and settlement on a planned tokenized-securities venue, fueling optimism about institutional adoption. Many are skeptical that the news will translate into lasting token demand, saying the initial pop faded and the gains are bleeding away.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Labs Q3 results sparked debate: revenue, backlog and forward guidance were strong, but a wider-than-expected loss weighed on shares after a recent run-up. Bulls point to growing launch demand and government support, while bears focus on ongoing losses and Neutrons delay to no earlier than 2027, with no firm launch date.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors HOPE-3 cardiac results received an American Heart Association research award, renewing optimism around deramiocel ahead of the FDAs November 22 decision. Traders are debating whether the recognition could support a cardiac label, while noting that the pending application centers on upper-limb function and approval remains uncertain after prior FDA concerns.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,957,873.22986632. The last known price of Zcash is 1,170.00468254 USD and is down -4.93 over the last 24 hours. It is currently trading on 669 active market(s) with $1,123,501,581.28 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs NU7 network upgrade is a major focus, with traders also debating the coins sharp swings after a strong rally. Bulls point to its privacy-focused appeal and relative resilience, while bears see the pullback as profit-taking and expect further downside.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell is joining a sharp semiconductor rebound, with traders speculating that Nvidia-related uncertainty is redirecting interest toward rivals such as Marvell, AMD and Broadcom. The bounce comes amid debate over the stocks steep recent decline, the proposed Lumentum deal and lingering concerns about AI infrastructure spending.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly results and raised full-year revenue outlook, fueled by BRIUMVI growth, are the main focus; traders welcomed the commercial momentum despite an EPS shortfall and a sharp selloff that reversed, with some attributing the volatility to short-seller activity. The Phase 3 readout for subcutaneous BRIUMVI is also a closely watched upcoming catalyst.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

A disappointing Q3 reportwith an unexpected loss, compressed margins, a weaker profit outlook, and a sequential subscriber declineis driving HIMSs sharp selloff. Bears question profitability and subscriber momentum, while bulls point to international growth, the Lilly partnership, and the planned peptides launch as potential offsets.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Attention centers on soquelitinibs potential across several clinical indications, with traders pointing to anticipated trial updates and reported institutional accumulation as reasons for optimism. Others remain skeptical, citing delayed or limited clinical data, the early-stage pipeline and ongoing cash burn; buyout and short-squeeze claims remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
